https://healthmonitorliechtenstein.com/article/905966552-vivos-therapeutics-reports-full-year-2025-financial-results Health Monitor Liechtenstein en PressRelease 2026-04-15T20:20:00+00:00 Vivos Therapeutics Reports Full Year 2025 Financial Results https://ml.globenewswire.com/media/22d07f60-2e17-421d-bbc3-748c2402061e/small/picture2-jpg.JPG https://healthmonitorliechtenstein.com/article/905968198-nexgel-reschedules-shareholder-update-conference-call-to-april-23rd-at-4-30-p-m-et-to-provide-update-on-celularity-transaction Health Monitor Liechtenstein en PressRelease 2026-04-15T20:12:00+00:00 NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity Transaction https://ml.globenewswire.com/media/0e76fff8-7aee-4b60-ba26-62dda9975939/small/logo-png.png https://healthmonitorliechtenstein.com/article/905967719-teladoc-health-to-announce-first-quarter-2026-financial-results Health Monitor Liechtenstein en PressRelease 2026-04-15T20:05:00+00:00 Teladoc Health to Announce First Quarter 2026 Financial Results https://ml.globenewswire.com/media/439ced23-c1ca-477b-8607-8067a1777d11/small/tdh-logo-png.png https://healthmonitorliechtenstein.com/article/905967914-adaptive-biotechnologies-to-report-first-quarter-2026-financial-results-on-may-5-2026 Health Monitor Liechtenstein en PressRelease 2026-04-15T20:05:00+00:00 Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026 https://ml.globenewswire.com/media/6c319974-0bac-45f1-83d9-ae9987dfdf44/small/adpt-new-logo-jpg.jpg https://healthmonitorliechtenstein.com/article/905966301-nkarta-announces-fda-agreement-on-outpatient-dosing-of-nkx019-in-autoimmune-disease-expanding-access-to-community-rheumatology-centers Health Monitor Liechtenstein en PressRelease 2026-04-15T20:01:00+00:00 Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers https://ml.globenewswire.com/media/09e7df7f-9555-45c9-bef1-86131c859ed3/small/nkarta-logo-2022-jpg.jpg https://healthmonitorliechtenstein.com/article/905966438-anika-to-issue-first-quarter-2026-financial-results-on-wednesday-april-29-2026 Health Monitor Liechtenstein en PressRelease 2026-04-15T20:01:00+00:00 Anika to Issue First Quarter 2026 Financial Results on Wednesday, April 29, 2026 https://ml.globenewswire.com/media/342e50d9-f0e4-4e79-b568-840299c2045d/small/anika-new-logo-blue-1200x628-png.png https://healthmonitorliechtenstein.com/article/905966946-wave-life-sciences-announces-proposed-redomiciliation-to-the-united-states Health Monitor Liechtenstein en PressRelease 2026-04-15T20:01:00+00:00 Wave Life Sciences Announces Proposed Redomiciliation to the United States https://ml.globenewswire.com/media/b2c5e218-8ae8-4dc2-b6f2-cf55b6b3b6e0/small/wave-life-sciences-logo-jpg.jpg https://healthmonitorliechtenstein.com/article/905967222-traws-pharma-reports-full-year-2025-results-and-provides-business-highlights Health Monitor Liechtenstein en PressRelease 2026-04-15T20:01:00+00:00 Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights https://ml.globenewswire.com/media/1eb1780a-724e-4555-ab4d-455e27d18544/small/traws-pharma-blue-png.png https://healthmonitorliechtenstein.com/article/905967681-algernon-health-announces-effective-date-of-previously-announced-name-change-to-grey-matters-health-inc-and-its-10-1-share-consolidation Health Monitor Liechtenstein en PressRelease 2026-04-15T20:01:00+00:00 Algernon Health Announces Effective Date of Previously Announced Name Change to “Grey Matters Health Inc.” and its 10:1 Share Consolidation https://ml.globenewswire.com/media/57ab3e9f-6614-45fb-863e-eb22d71c3d2a/small/picture1-jpg.jpg https://healthmonitorliechtenstein.com/article/905966572-elion-therapeutics-announces-initiation-of-turletricin-el219-phase-2-study-in-invasive-mould-infection Health Monitor Liechtenstein en PressRelease 2026-04-15T20:00:00+00:00 Elion Therapeutics Announces Initiation of Turletricin (EL219) Phase 2 Study in Invasive Mould Infection https://ml.globenewswire.com/media/4645f248-48c0-4a58-a2bd-f62e313e2b31/small/eliontx-logo-color-rgb-2-jpg.jpg https://healthmonitorliechtenstein.com/article/905967917-arcutis-to-report-first-quarter-2026-financial-results-and-host-conference-call-on-may-6-2026 Health Monitor Liechtenstein en PressRelease 2026-04-15T20:00:00+00:00 Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026 https://ml.globenewswire.com/media/1b166f47-afb1-44f1-91be-2d73e97c0ec3/small/arcutis-logo-png.png https://healthmonitorliechtenstein.com/article/905949618-the-association-for-frontotemporal-degeneration-aftd-hosts-first-capitol-hill-briefing-frontotemporal-degeneration-shining-a-light-on-a Health Monitor Liechtenstein en PressRelease 2026-04-15T19:20:27+00:00 The Association for Frontotemporal Degeneration (AFTD) Hosts First Capitol Hill Briefing: “Frontotemporal Degeneration: Shining a Light on a Little-Known Dementia” https://ml.globenewswire.com/media/OWJjOGJmOTctMmJmOC00NzExLTk5MTUtMmQ5N2EwNzBhZjk3LTEyNzYyMTctMjAyNi0wNC0xNS1lbg==/tiny/Association-for-Frontotemporal.png https://healthmonitorliechtenstein.com/article/905949656-svetlana-mojsov-one-of-the-scientists-behind-ozempic-and-mathematician-carlos-kenig-who-decoded-laws-of-motion-honored-as-king-faisal-prize-2026 Health Monitor Liechtenstein en PressRelease 2026-04-15T19:19:26+00:00 Svetlana Mojsov, one of the Scientists behind Ozempic, and Mathematician Carlos Kenig, who Decoded Laws of Motion, Honored as King Faisal Prize 2026 Laureates https://ml.globenewswire.com/media/NTZiODI3YmYtZjVkZC00NTIyLTgzMmYtMTNiYTkzYTMxMTM4LTEyNTgxNjctMjAyNi0wNC0xNS1lbg==/tiny/King-Faisal-Prize.png https://healthmonitorliechtenstein.com/article/905949203-shingles-raises-heart-and-stroke-risk-protect-yourself-with-vaccination Health Monitor Liechtenstein en PressRelease 2026-04-15T18:57:20+00:00 Shingles Raises Heart and Stroke Risk: Protect Yourself with Vaccination https://ml.globenewswire.com/Resource/Download/a116ab29-9104-48c4-bca2-d4435afdd0b3/17872-1.jpg https://healthmonitorliechtenstein.com/article/905948978-running-with-purpose-nashville-podiatrist-dr-lanier-shares-expert-tips-for-injury-free-half-marathon-training Health Monitor Liechtenstein en PressRelease 2026-04-15T18:45:36+00:00 Running with Purpose: Nashville Podiatrist Dr. Lanier Shares Expert Tips for Injury-Free Half Marathon Training https://ml.globenewswire.com/media/55db2f5c-a3dc-4282-9eba-d32817e25477/medium/family-fitness-in-action.jpeg https://healthmonitorliechtenstein.com/article/905947083-neutrolis-appoints-caren-deardorf-as-chief-business-strategy-officer Health Monitor Liechtenstein en PressRelease 2026-04-15T18:00:00+00:00 Neutrolis Appoints Caren Deardorf as Chief Business & Strategy Officer https://ml.globenewswire.com/media/44cdba09-fdb9-4ee1-b7bf-1dcfe5784800/small/20180228-opr-or-logos-biz-wd-neutrolis-logo-1-jpg.jpg https://healthmonitorliechtenstein.com/article/905933479-assureckd-appoints-former-lumiradx-technical-director-dr-aman-khan-as-chief-technology-officer-to-lead-diagnostic-platform-development Health Monitor Liechtenstein en PressRelease 2026-04-15T17:11:20+00:00 AssureCKD Appoints Former LumiraDx Technical Director Dr. Aman Khan as Chief Technology Officer to Lead Diagnostic Platform Development https://ml.globenewswire.com/media/MTI4MWJkOWEtNjkzNy00ZTYzLWI4OWMtZGZmNmRiMDA1N2ZiLTEzMjI2NjUtMjAyNi0wNC0xNS1lbg==/tiny/AssureCKD.png https://healthmonitorliechtenstein.com/article/905930843-basilea-aktion-re-genehmigen-an-der-generalversammlung-2026-alle-antr-ge-des-verwaltungsrats Health Monitor Liechtenstein en PressRelease 2026-04-15T16:30:00+00:00 Basilea-Aktionäre genehmigen an der Generalversammlung 2026 alle Anträge des Verwaltungsrats https://ml-eu.globenewswire.com/media/4403c5ae-6c9a-43d2-8c5f-deb2de747a47/small/basilea-logo-jpg.jpg https://healthmonitorliechtenstein.com/article/905931077-basilea-shareholders-approve-all-proposals-of-the-board-of-directors-at-the-2026-annual-general-meeting Health Monitor Liechtenstein en PressRelease 2026-04-15T16:30:00+00:00 Basilea shareholders approve all proposals of the board of directors at the 2026 annual general meeting https://ml-eu.globenewswire.com/media/4403c5ae-6c9a-43d2-8c5f-deb2de747a47/small/basilea-logo-jpg.jpg https://healthmonitorliechtenstein.com/article/905933265-onward-medical-launches-capital-increase-for-indicative-amount-of-eur-40-million Health Monitor Liechtenstein en PressRelease 2026-04-15T16:19:00+00:00 ONWARD Medical Launches Capital Increase for Indicative Amount of EUR 40 Million https://ml.globenewswire.com/media/a60261ec-0c66-4acb-8726-e567073990a2/small/onwardresized1-png.png https://healthmonitorliechtenstein.com/article/905932908-family-therapist-and-acclaimed-author-to-lead-webinar-on-healthy-co-parenting-boundaries Health Monitor Liechtenstein en PressRelease 2026-04-15T16:02:13+00:00 Family Therapist and Acclaimed Author to Lead Webinar on Healthy Co-Parenting Boundaries https://ml.globenewswire.com/media/N2RlYWJmOTktOWI0Mi00Nzg0LWJmM2QtZGRhZjgzM2QzYzMwLTEyNjU4MjMtMjAyNi0wNC0xNS1lbg==/tiny/TalkingParents.png https://healthmonitorliechtenstein.com/article/905916881-inteleos-foundation-medmissions-2026 Health Monitor Liechtenstein en PressRelease 2026-04-15T15:33:54+00:00 Inteleos Foundation تعلن عن جائزة MedMissions لعام 2026 لتعزيز نطاق الوصول إلى خدمات التصوير بالموجات فوق الصوتية لصحة الأم في خمس دول https://ml.globenewswire.com/media/ZTdkYjEwNGQtYWUwMS00N2JkLTg5NzctYzg2NTgxOGY1MmQxLTEyNDUwMzItMjAyNi0wNC0xNS1hcg==/tiny/Inteleos-Inc-.png https://healthmonitorliechtenstein.com/article/905916931-inteleos-foundation-annonce-les-laur-ats-du-prix-medmissions-2026-pour-renforcer-l-acc-s-l-chographie-maternelle-dans-cinq-nations Health Monitor Liechtenstein en PressRelease 2026-04-15T15:33:54+00:00 Inteleos Foundation annonce les lauréats du Prix MedMissions 2026 pour renforcer l’accès à l’échographie maternelle dans cinq nations https://ml.globenewswire.com/media/ZTdkYjEwNGQtYWUwMS00N2JkLTg5NzctYzg2NTgxOGY1MmQxLTEyNDUwMzItMjAyNi0wNC0xNS1mcg==/tiny/Inteleos-Inc-.png https://healthmonitorliechtenstein.com/article/905913948-what-if-you-could-reboot-sick-cells Health Monitor Liechtenstein en PressRelease 2026-04-15T15:00:00+00:00 What if you could reboot sick cells? https://ml-eu.globenewswire.com/media/e93daf2c-fee9-4db8-8c09-bab3a01da23b/medium/targeted-mitochondrial-delivery.jpg https://healthmonitorliechtenstein.com/article/905916100-cerene-by-channel-medsystems-partners-with-hey-girl-fund-to-support-menstrual-education-at-caregivers-girlies-brunch-on-saturday-april-18 Health Monitor Liechtenstein en PressRelease 2026-04-15T14:36:09+00:00 Cerene® by Channel Medsystems Partners with Hey Girl! Fund to Support Menstrual Education at Caregivers & Girlies Brunch on Saturday, April 18 https://ml.globenewswire.com/media/c8db1662-2442-4ba8-8910-6fe74312b2ee/small/channel-med-logo-1-jpg.jpg https://healthmonitorliechtenstein.com/article/905915517-nexalin-advances-fda-alzheimer-s-strategy-following-landmark-leadership-meetings-in-the-u-s-and-china Health Monitor Liechtenstein en PressRelease 2026-04-15T14:00:00+00:00 Nexalin Advances FDA Alzheimer’s Strategy Following Landmark Leadership Meetings in the U.S. and China https://ml.globenewswire.com/media/7f481b55-16b6-4c8a-8356-30d54079a605/small/nexalin-jpg.jpg https://healthmonitorliechtenstein.com/article/905898058-walking-yoga-app-how-combining-walking-and-yoga-accelerates-weight-loss Health Monitor Liechtenstein en PressRelease 2026-04-15T13:33:30+00:00 Walking Yoga App: How Combining Walking and Yoga Accelerates Weight Loss https://ml-eu.globenewswire.com/media/27e0ac34-ddfe-42a2-8a0b-7469fbf18c71/medium/walking-yoga-a-new-method-to-lose-weight.png https://healthmonitorliechtenstein.com/article/905902021-avita-medical-founder-fiona-wood-honored-with-lifetime-achievement-award-by-american-burn-association Health Monitor Liechtenstein en PressRelease 2026-04-15T13:20:00+00:00 AVITA Medical Founder Fiona Wood Honored with Lifetime Achievement Award by American Burn Association https://ml.globenewswire.com/media/53ad8139-952a-4470-9ede-2f3bf0521f16/small/avita-png.png https://healthmonitorliechtenstein.com/article/905901742-polaryx-therapeutics-recognized-with-pinnacle-award-for-excellence-in-pediatric-care Health Monitor Liechtenstein en PressRelease 2026-04-15T13:15:00+00:00 Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care https://ml.globenewswire.com/media/64e2f507-40e8-46aa-b22e-6661e7035467/small/polaryx-logonew-png.png https://healthmonitorliechtenstein.com/article/905903537-the-end-of-performance-at-any-cost-as-spider-silk-points-to-a-cleaner-future Health Monitor Liechtenstein en PressRelease 2026-04-15T13:15:00+00:00 The End of Performance at Any Cost, as Spider Silk Points to a Cleaner Future https://ml.globenewswire.com/media/NTA2YTQ4YmYtM2Q0Yy00YjkxLWIwZmYtYTNiZTk2YWRlMjYzLTUwMDE1MTA3NC0yMDI2LTA0LTE1LWVu/tiny/24-7-Market-News-and-Kraig-Lab.png https://healthmonitorliechtenstein.com/article/905900906-pacbio-and-covaris-announce-joint-workflow-enabling-hifi-long-read-sequencing-of-ffpe-tumor-samples Health Monitor Liechtenstein en PressRelease 2026-04-15T13:05:00+00:00 PacBio and Covaris Announce Joint Workflow Enabling HiFi Long-Read Sequencing of FFPE Tumor Samples https://ml.globenewswire.com/media/f408d681-e68c-4113-a7cd-be24486deefc/small/logo-centered-440x386-png.png https://healthmonitorliechtenstein.com/article/905901276-tango-therapeutics-announces-leadership-appointments-to-accelerate-late-stage-development-of-vopimetostat Health Monitor Liechtenstein en PressRelease 2026-04-15T13:05:00+00:00 Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat https://ml.globenewswire.com/media/d6e37a27-2e33-43bb-ae05-bfb0dedbf190/small/tango-logo-png.png https://healthmonitorliechtenstein.com/article/905903439-prophase-labs-reports-year-end-2025-results-highlights-accelerating-settlement-activity-and-investment-ready-crown-medical-collections-platform Health Monitor Liechtenstein en PressRelease 2026-04-15T13:05:00+00:00 ProPhase Labs Reports Year-End 2025 Results, Highlights Accelerating Settlement Activity and Investment-Ready Crown Medical Collections Platform https://ml.globenewswire.com/media/c6222831-7e36-422c-99fd-dff03828dc3a/small/logo-jpg.jpg https://healthmonitorliechtenstein.com/article/905903589-sienna-announces-april-dividend Health Monitor Liechtenstein en PressRelease 2026-04-15T13:00:23+00:00 Sienna Announces April Dividend https://ml.globenewswire.com/media/ac969f39-0111-4903-8faa-0cdee524eb4e/small/sienna-logo-rgb-jpg.jpg https://healthmonitorliechtenstein.com/article/905897427-annual-general-meeting-of-kuros-biosciences-approves-all-resolutions Health Monitor Liechtenstein en PressRelease 2026-04-15T13:00:00+00:00 Annual General Meeting of Kuros Biosciences approves all resolutions https://ml-eu.globenewswire.com/media/ad3777c9-af1f-4b09-a899-3b3d6b8e962d/small/kuros-logo-jpg.jpg https://healthmonitorliechtenstein.com/article/905898134-neuraclick-expands-scientific-and-translational-leadership-with-key-advisory-appointments Health Monitor Liechtenstein en PressRelease 2026-04-15T13:00:00+00:00 NeuraClick Expands Scientific and Translational Leadership with Key Advisory Appointments https://ml.globenewswire.com/media/04731e85-f435-4ef9-9077-b81361bf43f9/small/neuraclick-png-png.png https://healthmonitorliechtenstein.com/article/905901024-dogwood-therapeutics-announces-fda-acceptance-of-sp16-investigational-new-drug-application-for-the-treatment-of-chemotherapy-induced-pain-and Health Monitor Liechtenstein en PressRelease 2026-04-15T13:00:00+00:00 Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy https://ml.globenewswire.com/media/7fe5cc47-6599-477c-a858-0f0d9b9f7eb5/small/green-and-gray-png.png https://healthmonitorliechtenstein.com/article/905903583-alira-health-and-autoimmune-neurology-alliance-aina-launch-axis-registry-advancing-real-world-and-patient-centered-research-in-autoimmune-neurology Health Monitor Liechtenstein en PressRelease 2026-04-15T13:00:00+00:00 Alira Health and Autoimmune Neurology Alliance (AiNA) Launch AXIS Registry, Advancing Real-World and Patient-Centered Research in Autoimmune Neurology https://ml.globenewswire.com/media/c7422063-e642-4a37-86e3-d85294a19d12/small/alirahealth-jpg.jpg https://healthmonitorliechtenstein.com/article/905898276-just-salad-expands-in-washington-d-c Health Monitor Liechtenstein en PressRelease 2026-04-15T12:57:00+00:00 Just Salad Expands in Washington, D.C. https://ml.globenewswire.com/media/c9572eec-3547-4c38-987c-8a46d1b438f5/medium/interior-mural-at-1919-pennsylvania-avenue-nw.jpg https://healthmonitorliechtenstein.com/article/905903094-scientific-review-raises-questions-about-root-canal-safety-and-whole-body-health Health Monitor Liechtenstein en PressRelease 2026-04-15T12:50:00+00:00 Scientific Review Raises Questions About Root Canal Safety and Whole-Body Health https://ml.globenewswire.com/media/b6830cbc-f691-4b19-894a-b255e722ba81/medium/the-hidden-connection-root-canals-your-total-body-health.png https://healthmonitorliechtenstein.com/article/905901148-pds-biotech-announces-publication-of-positive-pds01adc-interim-phase-2-clinical-trial-data-from-stage-1-of-nci-led-metastatic-colorectal-cancer-mcrc Health Monitor Liechtenstein en PressRelease 2026-04-15T12:45:00+00:00 PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial https://ml.globenewswire.com/media/e2e7d124-dbd4-4140-9cc5-449d3488a902/small/pds-biotech-logo-png.png https://healthmonitorliechtenstein.com/article/905903520-vivos-therapeutics-schedules-release-of-full-year-2025-financial-results-and-conference-call Health Monitor Liechtenstein en PressRelease 2026-04-15T12:45:00+00:00 Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call https://ml.globenewswire.com/media/22d07f60-2e17-421d-bbc3-748c2402061e/small/picture2-jpg.JPG https://healthmonitorliechtenstein.com/article/905899926-biosyent-to-present-at-2026-bloom-burton-co-healthcare-investor-conference Health Monitor Liechtenstein en PressRelease 2026-04-15T12:40:00+00:00 BioSyent to Present at 2026 Bloom Burton & Co. Healthcare Investor Conference https://ml.globenewswire.com/media/3dded277-7953-4418-be63-7d7a3067811d/small/biosyent-logo-png.png https://healthmonitorliechtenstein.com/article/905900740-inteleos-foundation-announces-2026-medmissions-award-to-advance-maternal-health-ultrasound-access-in-five-nations Health Monitor Liechtenstein en PressRelease 2026-04-15T12:38:00+00:00 Inteleos Foundation Announces 2026 MedMissions Award to Advance Maternal Health Ultrasound Access in Five Nations https://ml.globenewswire.com/media/MGI2ZWI4MGItOTIzNi00ZGFlLWIxNzAtNmI5MjJjOGZkNjA1LTEyNDUwMzItMjAyNi0wNC0xNS1lbg==/tiny/Inteleos-Inc-.png https://healthmonitorliechtenstein.com/article/905898201-inspire-named-webby-awards-honoree-for-excellence-in-websites-mobile-sites-community Health Monitor Liechtenstein en PressRelease 2026-04-15T12:35:00+00:00 Inspire Named Webby Awards Honoree for Excellence in Websites & Mobile Sites - Community https://ml.globenewswire.com/media/ODg2MTE3YjktZWY4Yy00Y2U2LWI0MWUtYmY5MjYxYjQ2MWRlLTUwMDEyOTE4NC0yMDI2LTA0LTE1LWVu/tiny/Inspire.png https://healthmonitorliechtenstein.com/article/905897330-healport-raises-1-2m-usd-to-scale-global-digital-health-infrastructure Health Monitor Liechtenstein en PressRelease 2026-04-15T12:30:00+00:00 HealPort Raises 1.2M USD to Scale Global Digital Health Infrastructure https://ml-eu.globenewswire.com/media/d6eb6ad3-be4e-40b6-944e-9fac4d976b1e/small/img-20251206-wa0000-jpg.jpg https://healthmonitorliechtenstein.com/article/905898355-xenon-to-present-at-upcoming-investor-conferences Health Monitor Liechtenstein en PressRelease 2026-04-15T12:30:00+00:00 Xenon to Present at Upcoming Investor Conferences https://ml.globenewswire.com/media/505b89d3-dfd1-46e8-bc3b-3c9c699ef7ec/small/xenon-logo-tm-full-color-250x80px-png.png https://healthmonitorliechtenstein.com/article/905901283-allogene-therapeutics-announces-nature-communications-publication-highlighting-pre-clinical-data-for-allo-329-a-next-generation-dual-targeted Health Monitor Liechtenstein en PressRelease 2026-04-15T12:30:00+00:00 Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases https://ml.globenewswire.com/media/87e8712c-0741-409f-9942-c91b31e7c5e1/small/allogene-png.png https://healthmonitorliechtenstein.com/article/905899913-purchaser-business-group-on-health-unveils-results-of-2026-annual-member-survey-of-america-s-largest-employers Health Monitor Liechtenstein en PressRelease 2026-04-15T12:20:00+00:00 Purchaser Business Group on Health Unveils Results of ‘2026 Annual Member Survey’ of America’s Largest Employers https://ml.globenewswire.com/media/ZWE0Yjc4YjItYmYwNS00ZWVlLTllMjQtZDVjZjYwYjZmMmNkLTEyMTgzNzctMjAyNi0wNC0xNS1lbg==/tiny/Purchaser-Business-Group-on-He.png https://healthmonitorliechtenstein.com/article/905902991-traws-pharma-announces-up-to-60-million-private-placement-financing Health Monitor Liechtenstein en PressRelease 2026-04-15T12:15:00+00:00 Traws Pharma Announces Up to $60 Million Private Placement Financing https://ml.globenewswire.com/media/1eb1780a-724e-4555-ab4d-455e27d18544/small/traws-pharma-blue-png.png https://healthmonitorliechtenstein.com/article/905898273-billiontoone-to-report-first-quarter-2026-financial-results-on-may-6-2026 Health Monitor Liechtenstein en PressRelease 2026-04-15T12:05:00+00:00 BillionToOne to Report First Quarter 2026 Financial Results on May 6, 2026 https://ml.globenewswire.com/media/888ae54a-648f-4986-998b-84df416858c7/small/billion-to-one-logo-new-jpg.jpg https://healthmonitorliechtenstein.com/article/905902765-scienture-granted-180-day-extension-by-nasdaq-to-regain-compliance-with-minimum-bid-price-requirement Health Monitor Liechtenstein en PressRelease 2026-04-15T12:05:00+00:00 Scienture Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement https://ml.globenewswire.com/media/56382978-c242-4bdd-b491-e6966e27d4ed/small/logo-png.png https://healthmonitorliechtenstein.com/article/905897683-ardena-opens-new-bioanalytical-laboratory-in-somerset-new-jersey Health Monitor Liechtenstein en PressRelease 2026-04-15T12:02:10+00:00 Ardena Opens New Bioanalytical Laboratory in Somerset, New Jersey https://ml-eu.globenewswire.com/media/cf6817f0-2603-46b6-aa6b-1cbb814079c4/medium/ardena-u-s-facility-in-somerset-new-jersey.png https://healthmonitorliechtenstein.com/article/905898212-60-degrees-pharma-announces-arakoda-tafenoquine-for-malaria-prevention-is-now-available-on-runway-health-travel-website Health Monitor Liechtenstein en PressRelease 2026-04-15T12:02:00+00:00 60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel Website https://ml.globenewswire.com/media/c950cab5-27b1-476f-befc-4d92a7389fdd/small/60degrees-logo-rgb-logo-jpg.jpg https://healthmonitorliechtenstein.com/article/905897020-teva-launches-home-ground-schizophrenia-community-a-new-online-resource-hub-for-people-living-with-schizophrenia-and-their-care-partners Health Monitor Liechtenstein en PressRelease 2026-04-15T12:00:00+00:00 Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners https://ml-eu.globenewswire.com/media/c2001734-949b-4cc2-8021-b4b64eda1f13/small/teva-rgb-jpeg-jpg.jpg https://healthmonitorliechtenstein.com/article/905897206-boehringer-ingelheim-and-zai-lab-announce-collaboration-on-dll3-targeting-t-cell-engager-and-adc-combination-in-small-cell-lung-cancer-and-other Health Monitor Liechtenstein en PressRelease 2026-04-15T12:00:00+00:00 Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas https://ml-eu.globenewswire.com/media/f121dfae-77e7-4a01-b1ef-6b757767ddab/small/111boehringer-ingelheim-logo-rgb-dark-green-002-png.png https://healthmonitorliechtenstein.com/article/905897922-folia-health-launches-brave-pws-study-to-better-understand-the-real-world-experience-of-prader-willi-syndrome-caregivers Health Monitor Liechtenstein en PressRelease 2026-04-15T12:00:00+00:00 Folia Health Launches “BRAVE-PWS” Study to Better Understand the Real-World Experience of Prader-Willi Syndrome Caregivers https://ml.globenewswire.com/media/858e11f4-96a0-4321-93eb-d278df849ccf/small/untitled-design-1-png.png https://healthmonitorliechtenstein.com/article/905898344-amarin-to-report-first-quarter-2026-financial-results-and-host-conference-call-on-april-29-2026 Health Monitor Liechtenstein en PressRelease 2026-04-15T12:00:00+00:00 Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 https://ml.globenewswire.com/media/00eeab93-e634-4279-86b3-7973c2a21623/small/amarin-logo-jpeg-jpg.jpg https://healthmonitorliechtenstein.com/article/905898944-sab-bio-to-present-additional-data-supporting-the-unique-profile-of-sab-142-at-the-2026-immunology-of-diabetes-society-congress Health Monitor Liechtenstein en PressRelease 2026-04-15T12:00:00+00:00 SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress https://ml.globenewswire.com/media/6d99a771-f2c9-4d05-bf57-4f6c070df032/small/sabprimarylogocolorrgb900px72ppi-png.png https://healthmonitorliechtenstein.com/article/905899215-cue-biopharma-to-present-new-preclinical-data-on-lead-autoimmune-and-inflammatory-disease-candidate-cue-401-at-immunology2026 Health Monitor Liechtenstein en PressRelease 2026-04-15T12:00:00+00:00 Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026 https://ml.globenewswire.com/media/10541379-34cc-4869-a26f-fd99feead42a/small/cue-bio-brand-strategy-graphics-jpg.jpg https://healthmonitorliechtenstein.com/article/905900529-picard-medical-syncardia-highlights-total-artificial-heart-bridge-to-transplant-case-at-texas-children-s-hospital Health Monitor Liechtenstein en PressRelease 2026-04-15T12:00:00+00:00 Picard Medical / SynCardia Highlights Total Artificial Heart Bridge to Transplant Case at Texas Children's Hospital https://ml.globenewswire.com/media/93c733bb-b54a-41af-856b-6d01c1f724a2/small/syncardia-x-picard-email-signature-2025-1-png.png https://healthmonitorliechtenstein.com/article/905901251-beyond-air-to-participate-in-the-d-boral-capital-global-conference-2026 Health Monitor Liechtenstein en PressRelease 2026-04-15T12:00:00+00:00 Beyond Air to Participate in the D. Boral Capital Global Conference 2026 https://ml.globenewswire.com/media/c7ae3957-2763-4e5c-9594-57e1ba60ed59/small/beyond-air-the-magic-of-breathing-png.png https://healthmonitorliechtenstein.com/article/905901370-immutep-receives-fda-orphan-drug-designation-for-eftilagimod-alfa-in-soft-tissue-sarcoma Health Monitor Liechtenstein en PressRelease 2026-04-15T12:00:00+00:00 Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma https://ml.globenewswire.com/media/b2cd55d0-59ab-45ac-a1fe-5cf2adac7f24/small/immutep-new-logo-png.png https://healthmonitorliechtenstein.com/article/905901585-reviva-announces-letter-to-shareholders Health Monitor Liechtenstein en PressRelease 2026-04-15T12:00:00+00:00 Reviva Announces Letter to Shareholders https://ml.globenewswire.com/media/1d8c6564-1da5-4561-b6ec-79de6d565869/small/reviva-logo-png.png https://healthmonitorliechtenstein.com/article/905901758-calidi-biotherapeutics-announces-participation-in-redchip-s-april-16-virtual-investor-conference-to-feature-companies-advancing-clinical-pipelines-and Health Monitor Liechtenstein en PressRelease 2026-04-15T12:00:00+00:00 Calidi Biotherapeutics Announces Participation in RedChip’s April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms https://ml.globenewswire.com/media/9e574b79-be62-4805-a4b4-cb0b7dcc5fbd/small/calidibiotherapeutics-logo-2x-jpg.jpg https://healthmonitorliechtenstein.com/article/905902114-filana-therapeutics-announces-publication-in-epilepsia-of-preclinical-simufilam-data Health Monitor Liechtenstein en PressRelease 2026-04-15T12:00:00+00:00 Filana Therapeutics Announces Publication in Epilepsia of Preclinical Simufilam Data https://ml.globenewswire.com/media/877131cb-f6f1-4b81-99c9-d2ea829a9272/medium/epilepsia-paper-figure-3c.png https://healthmonitorliechtenstein.com/article/905902287-achieve-life-sciences-announces-operational-progress-including-completion-of-technology-transfer-to-adare-pharma-solutions Health Monitor Liechtenstein en PressRelease 2026-04-15T12:00:00+00:00 Achieve Life Sciences Announces Operational Progress Including Completion of Technology Transfer to Adare Pharma Solutions https://ml.globenewswire.com/media/1026e030-275c-4391-8f9a-65c5c1ec7b88/small/achieve-logo-717x800px-2-1-jpg.jpg https://healthmonitorliechtenstein.com/article/905902588-callio-therapeutics-to-present-poster-on-clio-8221-a-novel-dual-payload-antibody-drug-conjugate-at-aacr-2026 Health Monitor Liechtenstein en PressRelease 2026-04-15T12:00:00+00:00 Callio Therapeutics to Present Poster on CLIO-8221, a Novel Dual-Payload Antibody-Drug Conjugate, at AACR 2026 https://ml.globenewswire.com/media/3511fd62-eaba-4921-a3da-4e0b00d976e6/small/callio-logo-stacked-default-png.png https://healthmonitorliechtenstein.com/article/905902871-extendicare-announces-april-2026-dividend-of-c-0-0441-per-share Health Monitor Liechtenstein en PressRelease 2026-04-15T12:00:00+00:00 Extendicare Announces April 2026 Dividend of C$0.0441 per Share https://ml.globenewswire.com/media/6d631964-eede-4e2c-912c-58ab7d1dc35f/small/extendicare-jpg.jpg https://healthmonitorliechtenstein.com/article/905902924-ai-enabled-fertility-care-and-longevity-provider-onto-health-closes-20-million-series-funded-by-artis-and-humania Health Monitor Liechtenstein en PressRelease 2026-04-15T11:52:00+00:00 AI-Enabled Fertility Care and Longevity Provider ONTO Health Closes $20 Million Series funded by ARTIS and Humania https://ml.globenewswire.com/media/bfd2a283-62a3-4223-a85d-f2bbd3a71ec6/small/16017175-5a43-4a1c-bd49-824adef1a0fb-png.png https://healthmonitorliechtenstein.com/article/905880835-tilray-brands-accelerates-next-phase-of-global-growth-and-market-leadership Health Monitor Liechtenstein en PressRelease 2026-04-15T11:40:44+00:00 Tilray Brands Accelerates Next Phase of Global Growth and Market Leadership https://ml.globenewswire.com/media/2dbf85bb-5e30-4623-8f9b-931442240c05/small/tilraybrands-logo-fullcolor-rbg-horiz-01-png.png https://healthmonitorliechtenstein.com/article/905879486-inside-the-science-new-white-paper-explores-the-injection-set-to-redefine-the-treatment-of-knee-osteoarthritis-unlock-access-to-non-surgical Health Monitor Liechtenstein en PressRelease 2026-04-15T11:30:17+00:00 Inside the Science: New White Paper Explores the Injection Set to Redefine the Treatment of Knee Osteoarthritis & Unlock Access to Non-Surgical Options for Patients on the NHS https://ml-eu.globenewswire.com/media/OTcxNDdjMzktYjc5Yy00ODFkLWE3MGMtNDQyNDE5MGY5NjZiLTEzMjI2NDUtMjAyNi0wNC0xNS1lbg==/tiny/Contura-Orthopaedics-Ltd.png https://healthmonitorliechtenstein.com/article/905879341-medicus-pharma-to-present-new-teverelix-data-at-aace-2026-demonstrating-long-acting-hormone-suppression Health Monitor Liechtenstein en PressRelease 2026-04-15T11:30:00+00:00 Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression https://ml.globenewswire.com/media/0f5af1d1-dfba-4810-baac-d1922c0558c1/small/medicus-logo-rgb-05-aspect-1500px-globe-newswire-2-jpg.jpg https://healthmonitorliechtenstein.com/article/905879590-brainsway-highlights-growing-u-s-payer-support-for-nurse-practitioner-administered-transcranial-magnetic-stimulation-tms-therapy Health Monitor Liechtenstein en PressRelease 2026-04-15T11:30:00+00:00 BrainsWay Highlights Growing U.S. Payer Support for Nurse Practitioner-Administered Transcranial Magnetic Stimulation (TMS) Therapy https://ml.globenewswire.com/media/ea01c8f7-39be-46d2-a8e0-bc05994f170e/small/brainsway-2021-logo-jpg.jpg https://healthmonitorliechtenstein.com/article/905879729-arbutus-receives-u-s-fda-fast-track-designation-for-imdusiran-for-the-treatment-of-chronic-hepatitis-b Health Monitor Liechtenstein en PressRelease 2026-04-15T11:30:00+00:00 Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B https://ml.globenewswire.com/media/be474abd-3f6d-4270-a58e-1e6ee5c80bb2/small/arbutus-biopharma-logo.jpg https://healthmonitorliechtenstein.com/article/905879994-plus-therapeutics-appoints-randy-h-goodman-phd-mha-as-vice-president-of-value-strategy-heor-to-advance-market-access-and-commercial-execution Health Monitor Liechtenstein en PressRelease 2026-04-15T11:30:00+00:00 Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution https://ml.globenewswire.com/media/92d7aa70-e37d-4870-bccf-d83b68ba5612/small/plus-logo-png.png https://healthmonitorliechtenstein.com/article/905880421-prelude-therapeutics-announces-the-appointment-of-charles-morris-m-d-as-chief-medical-officer Health Monitor Liechtenstein en PressRelease 2026-04-15T11:30:00+00:00 Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer https://ml.globenewswire.com/media/cab62748-b61a-42cb-b552-b0c6c91c4e83/small/ptx-logo-png.png https://healthmonitorliechtenstein.com/article/905880501-tg-therapeutics-announces-completion-of-enrollment-for-the-phase-3-trial-evaluating-subcutaneous-briumvi Health Monitor Liechtenstein en PressRelease 2026-04-15T11:30:00+00:00 TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI https://ml.globenewswire.com/media/0e613f5f-8c22-4c63-a73b-c08cc0fbec64/small/tgtx-2021-logo.jpg https://healthmonitorliechtenstein.com/article/905880748-clearmind-medicine-announces-positive-data-safety-monitoring-board-recommendation-in-ongoing-cmnd-100-clinical-trial Health Monitor Liechtenstein en PressRelease 2026-04-15T11:30:00+00:00 Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial https://ml.globenewswire.com/media/bd17cbf4-8124-4f86-8a4c-1fafbb6785af/small/logo-jpg.jpg https://healthmonitorliechtenstein.com/article/905880639-alterity-therapeutics-to-host-virtual-kol-event-to-share-new-insights-on-ath434-for-the-treatment-of-multiple-system-atrophy Health Monitor Liechtenstein en PressRelease 2026-04-15T11:25:00+00:00 Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy https://ml.globenewswire.com/media/0771a9a2-2ac1-4a63-9767-a2b1df74af27/small/alterity-png.png https://healthmonitorliechtenstein.com/article/905879871-stereotaxis-announces-definitive-agreement-to-acquire-robocath Health Monitor Liechtenstein en PressRelease 2026-04-15T11:00:00+00:00 Stereotaxis Announces Definitive Agreement to Acquire Robocath https://ml.globenewswire.com/media/95a5b8ca-b7c0-4c80-8ca7-063ef10706c3/small/stereotaxis-logo-new-tagline-black-text-png.png https://healthmonitorliechtenstein.com/article/905879928-biocryst-to-report-first-quarter-2026-financial-results-on-may-6 Health Monitor Liechtenstein en PressRelease 2026-04-15T11:00:00+00:00 BioCryst to Report First Quarter 2026 Financial Results on May 6 https://ml.globenewswire.com/media/8b033909-1a3c-4811-b07b-fe03b12e00d2/small/biocryst-primarylogo-r-2c-rgb-jpg.jpg https://healthmonitorliechtenstein.com/article/905880212-orvida-pharma-formerly-kamari-pharma-announces-favorable-phase-1a-safety-data-for-km-023-a-potential-first-in-disease-oral-trpv3-inhibitor-and Health Monitor Liechtenstein en PressRelease 2026-04-15T11:00:00+00:00 Orvida Pharma (formerly Kamari Pharma) Announces Favorable Phase 1a Safety Data for KM-023, a Potential First-in-Disease Oral TRPV3 Inhibitor, and Initiation of Phase 1b Study in Patients with Olmsted Syndrome https://ml.globenewswire.com/media/cd4d7fc1-6bca-4b1d-a6b3-2314ed21fb79/small/orvida-final-46-jpg.jpg https://healthmonitorliechtenstein.com/article/905880223-tonix-pharmaceuticals-announces-publication-of-steady-state-pharmacokinetics-of-tonmya-after-20-days-of-daily-dosing-in-the-peer-reviewed-journal Health Monitor Liechtenstein en PressRelease 2026-04-15T11:00:00+00:00 Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development https://ml.globenewswire.com/media/16aad249-3d33-4501-b3d9-118a703fa46e/small/tonix2-jpg.jpg https://healthmonitorliechtenstein.com/article/905880323-beeline-medicines-debuts-to-deliver-category-leading-precision-therapies-for-people-living-with-autoimmune-and-inflammatory-diseases Health Monitor Liechtenstein en PressRelease 2026-04-15T11:00:00+00:00 Beeline Medicines Debuts to Deliver Category-Leading Precision Therapies for People Living with Autoimmune and Inflammatory Diseases https://ml.globenewswire.com/media/a870f826-b54c-4781-bf10-d8ce2db7245a/small/beelinemedicines-logo-fullcolor-png.png https://healthmonitorliechtenstein.com/article/905880568-nrx-pharmaceuticals-advances-robotic-enabled-transcranial-magnetic-stimulation-combined-with-neuroplastic-therapy-for-military-and-first-responder Health Monitor Liechtenstein en PressRelease 2026-04-15T11:00:00+00:00 NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications https://ml.globenewswire.com/media/d879f1ff-d5d7-48d7-9731-c881b469d873/small/nrx-logo-300dpi-png.png https://healthmonitorliechtenstein.com/article/905880425-neffy-epinephrine-nasal-spray-approved-in-canada-as-the-first-and-only-needle-free-emergency-treatment-of-allergic-reactions-anaphylaxis Health Monitor Liechtenstein en PressRelease 2026-04-15T10:05:00+00:00 neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) https://ml.globenewswire.com/media/8feeb9d1-ed0c-491a-988b-a2b54778e825/small/ars-logo-png.png https://healthmonitorliechtenstein.com/article/905862956-alivecor-bringt-das-ki-gest-tzte-kardia-12l-in-europa-auf-den-markt-das-weltweit-erste-tragbare-12-kanal-ekg-mit-einzigartigem-ein-kabel-design Health Monitor Liechtenstein en PressRelease 2026-04-15T08:01:00+00:00 AliveCor bringt das KI-gestützte Kardia 12L in Europa auf den Markt: Das weltweit erste tragbare 12-Kanal-EKG mit einzigartigem Ein-Kabel-Design https://ml.globenewswire.com/media/ca97a5ad-9227-4559-a41a-59468d5bc246/small/alivecor-rgb-horizontal-blue-2-png.png https://healthmonitorliechtenstein.com/article/905863061-alivecor-lanza-en-europa-el-kardia-12l-un-dispositivo-con-ia-el-primer-ecg-port-til-de-12-derivaciones-del-mundo-con-un-dise-o-nico-de-un-solo Health Monitor Liechtenstein en PressRelease 2026-04-15T08:01:00+00:00 AliveCor lanza en Europa el Kardia 12L, un dispositivo con IA: el primer ECG portátil de 12 derivaciones del mundo con un diseño único de un solo cable https://ml.globenewswire.com/media/ca97a5ad-9227-4559-a41a-59468d5bc246/small/alivecor-rgb-horizontal-blue-2-png.png https://healthmonitorliechtenstein.com/article/905863140-lancement-par-alivecor-du-kardia-12l-aliment-par-l-ia-en-europe-le-premier-ecg-portable-12-d-rivations-au-monde-dot-d-une-conception-in-dite Health Monitor Liechtenstein en PressRelease 2026-04-15T08:01:00+00:00 Lancement par AliveCor du Kardia 12L alimenté par l’IA en Europe : le premier ECG portable à 12 dérivations au monde, doté d’une conception inédite à câble unique https://ml.globenewswire.com/media/ca97a5ad-9227-4559-a41a-59468d5bc246/small/alivecor-rgb-horizontal-blue-2-png.png https://healthmonitorliechtenstein.com/article/905863200-alivecor-lancia-in-europa-kardia-12l-basato-su-intelligenza-artificiale-il-primo-ecg-portatile-a-12-derivazioni-al-mondo-con-un-esclusivo-design-a Health Monitor Liechtenstein en PressRelease 2026-04-15T08:01:00+00:00 AliveCor lancia in Europa Kardia 12L basato su intelligenza artificiale: il primo ECG portatile a 12 derivazioni al mondo con un esclusivo design a cavo singolo https://ml.globenewswire.com/media/ca97a5ad-9227-4559-a41a-59468d5bc246/small/alivecor-rgb-horizontal-blue-2-png.png https://healthmonitorliechtenstein.com/article/905863241-alivecor-lanceert-de-ai-gestuurde-kardia-12l-in-europa-s-werelds-eerste-draagbare-12-afleidingen-ecg-met-een-uniek-ontwerp-met-n-kabel Health Monitor Liechtenstein en PressRelease 2026-04-15T08:01:00+00:00 AliveCor lanceert de AI-gestuurde Kardia 12L in Europa: 's werelds eerste draagbare 12-afleidingen-ECG met een uniek ontwerp met één kabel https://ml.globenewswire.com/media/ca97a5ad-9227-4559-a41a-59468d5bc246/small/alivecor-rgb-horizontal-blue-2-png.png https://healthmonitorliechtenstein.com/article/905863456-alivecor-launches-ai-powered-kardia-12l-in-europe-the-world-s-first-handheld-12-lead-ecg-with-a-unique-single-cable-design Health Monitor Liechtenstein en PressRelease 2026-04-15T08:01:00+00:00 AliveCor Launches AI-Powered Kardia 12L in Europe: The World’s First Handheld 12-Lead ECG with a Unique Single-Cable Design https://ml.globenewswire.com/media/d510c9dc-7eb1-45bd-ba22-aa01f14d3e40/medium/alivecor-s-kardia-12l-launches-in-europe.png https://healthmonitorliechtenstein.com/article/905862487-c-mo-medical-solutions-receives-ce-mark-for-its-novel-ai-powered-cough-monitoring-solution Health Monitor Liechtenstein en PressRelease 2026-04-15T08:00:00+00:00 C-mo Medical Solutions Receives CE Mark for Its Novel AI-Powered Cough Monitoring Solution https://ml-eu.globenewswire.com/media/MjJkZjIyNmItZDRjYi00MjIyLWI0ZTgtNGU4MzI0MjEyN2FiLTEwMzc0NTQtMjAyNi0wNC0xNS1lbg==/tiny/AKAMPION.png https://healthmonitorliechtenstein.com/article/905843465-minervax-strengthens-executive-leadership-team-with-two-strategic-appointments-as-it-advances-its-maternal-gbs-vaccine-towards-pivotal-trial Health Monitor Liechtenstein en PressRelease 2026-04-15T07:30:00+00:00 MinervaX Strengthens Executive Leadership Team with Two Strategic Appointments as it Advances its Maternal GBS Vaccine Towards Pivotal Trial Initiation https://ml-eu.globenewswire.com/media/e8d7e6c7-c95d-4c2e-85d8-7c656c5ee8f5/small/minervax-logo-png.png https://healthmonitorliechtenstein.com/article/905844405-notice-of-issuance-of-new-shares-in-connection-with-the-introduction-of-the-employee-stock-ownership-plan-matters-relating-to-stock-units-and Health Monitor Liechtenstein en PressRelease 2026-04-15T06:34:41+00:00 Notice of Issuance of New Shares in Connection with the Introduction of the Employee Stock Ownership Plan, Matters Relating to Stock Units and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Prior RSU Award https://ml-eu.globenewswire.com/media/5cc74d52-c86f-4e21-8684-3496281fee15/small/nxera-master-logo-rgb-black-1-png.png https://healthmonitorliechtenstein.com/article/905844939-clinuvel-advancing-peptides-for-photomedicine-and-vitiligo-care-at-aad-2026 Health Monitor Liechtenstein en PressRelease 2026-04-15T06:18:07+00:00 CLINUVEL: advancing peptides for photomedicine and vitiligo care at AAD 2026 https://ml.globenewswire.com/media/a63efa41-50f1-45f2-8ee5-0d54842edcaa/medium/clinuvels-pavilion-of-photomedicine-at-aad-2026.jpg https://healthmonitorliechtenstein.com/article/905843826-aerska-strengthens-leadership-and-board-with-key-appointments-to-advance-systemically-delivered-rna-medicines-for-the-brain Health Monitor Liechtenstein en PressRelease 2026-04-15T06:00:00+00:00 Aerska Strengthens Leadership and Board with Key Appointments to Advance Systemically Delivered RNA Medicines for the Brain https://ml-eu.globenewswire.com/media/a4eb676a-dff5-4c91-a519-c5b46087f6f1/small/aerska-logo-1-png.png https://healthmonitorliechtenstein.com/article/905843928-citryll-strengthens-intellectual-property-portfolio-with-grant-of-european-composition-of-matter-patent-for-cit-013 Health Monitor Liechtenstein en PressRelease 2026-04-15T06:00:00+00:00 Citryll Strengthens Intellectual Property Portfolio With Grant of European Composition of Matter Patent for CIT-013 https://ml-eu.globenewswire.com/media/34e26d4c-9c72-4edc-a853-633cca05b108/small/1-citryll-logo-rgb-002-png.png https://healthmonitorliechtenstein.com/article/905824743-ose-immunotherapeutics-to-present-a-novel-first-in-class-fpr2-agonist-monoclonal-antibody-in-the-resolution-of-chronic-inflammation-at-the-aai-2026 Health Monitor Liechtenstein en PressRelease 2026-04-15T05:30:00+00:00 OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at the AAI 2026 Meeting https://ml-eu.globenewswire.com/media/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22/small/ose-logo-horizontal-rvb-png.png https://healthmonitorliechtenstein.com/article/905824755-ose-immunotherapeutics-pr-sentera-un-nouvel-anticorps-monoclonal-first-in-class-agoniste-de-fpr2-dans-la-r-solution-de-l-inflammation-chronique-au Health Monitor Liechtenstein en PressRelease 2026-04-15T05:30:00+00:00 OSE Immunotherapeutics présentera un nouvel anticorps monoclonal, first-in-class, agoniste de FPR2 dans la résolution de l’inflammation chronique au Congrès 2026 de l’AAI https://ml-eu.globenewswire.com/media/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22/small/ https://healthmonitorliechtenstein.com/article/905824846-bioversys-to-present-data-on-clinical-and-preclinical-pipeline-programs-at-escmid-global-2026 Health Monitor Liechtenstein en PressRelease 2026-04-15T05:00:00+00:00 BioVersys to Present Data on Clinical and Preclinical Pipeline Programs at ESCMID Global 2026 https://ml.globenewswire.com/media/37dee549-5eb0-418f-a16c-11d8422babfb/small/logo-bioversys-color-rgb-neu-for-prs-jpg.jpg https://healthmonitorliechtenstein.com/article/905824961-revolution-medicines-inc-prices-2-0-billion-in-concurrent-upsized-offerings-of-common-stock-and-convertible-senior-notes Health Monitor Liechtenstein en PressRelease 2026-04-15T04:41:13+00:00 Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes https://ml.globenewswire.com/media/771b34d9-586d-435a-a976-ab0ab847571b/small/balanced-green-primary-logo-medium-1000px-png.png https://healthmonitorliechtenstein.com/article/905808332-spyre-therapeutics-announces-pricing-of-upsized-403-0-million-public-offering-of-common-stock Health Monitor Liechtenstein en PressRelease 2026-04-15T02:38:25+00:00 Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock https://ml.globenewswire.com/media/bc26a912-b583-43c6-8423-55a4ba2bf4bd/small/spyre-logo-horizontal-full-color-rgb-583px-300ppi-jpg.jpg https://healthmonitorliechtenstein.com/article/905808311-lecom-makes-pharmacy-education-more-accessible-with-three-fully-accredited-doctor-of-pharmacy-pathways Health Monitor Liechtenstein en PressRelease 2026-04-15T02:31:27+00:00 LECOM Makes Pharmacy Education More Accessible with Three Fully Accredited Doctor of Pharmacy Pathways https://ml.globenewswire.com/Resource/Download/53969c12-c282-4b1a-a914-4ac7480a61e3/image1.jpeg https://healthmonitorliechtenstein.com/article/905790975-allogene-therapeutics-announces-pricing-of-public-offering-of-common-stock Health Monitor Liechtenstein en PressRelease 2026-04-15T01:50:00+00:00 Allogene Therapeutics Announces Pricing of Public Offering of Common Stock https://ml.globenewswire.com/media/87e8712c-0741-409f-9942-c91b31e7c5e1/small/allogene-png.png https://healthmonitorliechtenstein.com/article/905790950-american-addiction-centers-and-filmmaker-jeffrey-shulman-team-up-to-promote-powerful-new-film-on-addiction-and-recovery-with-national-theatrical-tour Health Monitor Liechtenstein en PressRelease 2026-04-15T01:17:26+00:00 American Addiction Centers and Filmmaker Jeffrey Shulman Team Up to Promote Powerful New Film on Addiction and Recovery with National Theatrical Tour https://ml.globenewswire.com/media/1cd36806-58ee-4d6f-935f-bd2088746d5d/medium/what-it-takes-official-film-poster.JPG https://healthmonitorliechtenstein.com/article/905790908-arc-trt-launches-new-website-to-help-uk-men-access-personalised-testosterone-replacement-therapy Health Monitor Liechtenstein en PressRelease 2026-04-15T01:03:33+00:00 Arc TRT Launches New Website to Help UK Men Access Personalised Testosterone Replacement Therapy https://ml.globenewswire.com/media/adfa345c-868c-4bca-bdda-15d2ab4d6315/small/arc-trt-png.png https://healthmonitorliechtenstein.com/article/905791055-epimab-biotherapeutics-to-present-a-novel-prodrug-t-cell-engager-protce-platform-at-the-2026-american-association-for-cancer-research-annual-meeting Health Monitor Liechtenstein en PressRelease 2026-04-15T01:00:00+00:00 EpimAb Biotherapeutics to Present a Novel Prodrug T-Cell Engager (ProTCE) Platform at the 2026 American Association for Cancer Research Annual Meeting https://ml.globenewswire.com/media/fa1bd13e-e49a-4b2c-a742-85957a03ad87/small/epimab-logo-for-notified-png.png https://healthmonitorliechtenstein.com/article/905776369-mesoblast-acquires-chimeric-antigen-receptor-car-platform-technology-for-precision-enhanced-cell-products Health Monitor Liechtenstein en PressRelease 2026-04-15T00:10:56+00:00 Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products https://ml.globenewswire.com/media/a9938a8a-a0ba-4708-abd5-2219515343fc/small/mesologo-png.png https://healthmonitorliechtenstein.com/article/905776367-telix-doses-first-patient-in-phase-3-ipax-bright-trial-of-tlx101-tx-for-recurrent-glioblastoma Health Monitor Liechtenstein en PressRelease 2026-04-14T23:04:43+00:00 Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma https://ml.globenewswire.com/media/77ceffdf-31cc-415f-9747-efee950af329/small/telix-main-logo-3-png.png https://healthmonitorliechtenstein.com/article/905763136-bruno-mars-presents-1-million-gift-to-intermountain-health-for-the-future-nevada-children-s-hospital Health Monitor Liechtenstein en PressRelease 2026-04-14T21:40:23+00:00 Bruno Mars Presents $1 Million Gift to Intermountain Health for the Future Nevada Children’s Hospital https://ml.globenewswire.com/media/OGZmZTRlNzItNGMwOS00NDY4LWJlNzgtZGRiNjk5Mjc4ODU1LTEyNjkxMjYtMjAyNi0wNC0xNC1lbg==/tiny/Intermountain-Health.png https://healthmonitorliechtenstein.com/article/905763051-lymph-tonic-claims-evaluated-the-forbidden-enzyme-protocol-for-safe-weight-loss-support-by-lymphtonic Health Monitor Liechtenstein en PressRelease 2026-04-14T21:37:48+00:00 Lymph Tonic Claims Evaluated: The Forbidden Enzyme Protocol for Safe Weight Loss Support by LymphTonic https://zingfast.com/wp-content/uploads/2026/04/Lymph-Tonic.jpg https://healthmonitorliechtenstein.com/article/905762991-enlitic-announces-ensight-2-2-a-breakthrough-in-imaging-data-standardization Health Monitor Liechtenstein en PressRelease 2026-04-14T21:29:27+00:00 Enlitic Announces Ensight 2.2, a Breakthrough in Imaging Data Standardization https://ml.globenewswire.com/media/372da620-5254-4763-8d1e-53195694c648/medium/enlitic-announces-ensight-2-2-a-breakthrough-in-imaging-data.jpg https://healthmonitorliechtenstein.com/article/905750683-lemaitre-will-announce-first-quarter-2026-earnings-results-on-may-5-2026 Health Monitor Liechtenstein en PressRelease 2026-04-14T20:54:05+00:00 LeMaitre Will Announce First Quarter 2026 Earnings Results on May 5, 2026 https://ml.globenewswire.com/media/8b8755b7-6f04-4650-9c94-0a2d0654fd49/small/lemaitre-2color-rgb-jpg.jpg https://healthmonitorliechtenstein.com/article/905749724-ankalax-claims-evaluated-effective-ankle-massager-brace-with-heat-therapy-vibration-compression-for-recovery Health Monitor Liechtenstein en PressRelease 2026-04-14T20:28:01+00:00 Ankalax Claims Evaluated: Effective Ankle Massager Brace with Heat Therapy + Vibration Compression for Recovery https://zingfast.com/wp-content/uploads/2026/04/Ankalax-Ankle-Massage-Brace.jpg https://healthmonitorliechtenstein.com/article/905749617-update-r1-announces-phare-os-expansion-to-help-providers-navigate-growing-complexity-and-margin-pressure Health Monitor Liechtenstein en PressRelease 2026-04-14T20:25:34+00:00 UPDATE - R1 Announces Phare OS Expansion to Help Providers Navigate Growing Complexity and Margin Pressure https://ml.globenewswire.com/media/728189a4-e254-443f-8452-315403fd70f4/small/r1-logo-black-25-947x676-jpg.jpg https://healthmonitorliechtenstein.com/article/905748202-heartsciences-reminds-its-shareholders-to-submit-their-vote-at-the-upcoming-april-30-2026-annual-shareholders-meeting Health Monitor Liechtenstein en PressRelease 2026-04-14T20:15:00+00:00 HeartSciences Reminds Its Shareholders to Submit Their Vote at the Upcoming April 30, 2026, Annual Shareholders Meeting https://ml.globenewswire.com/media/800a6aae-74f3-42bb-9199-5e169ed9b881/small/heartsciences-png.png https://healthmonitorliechtenstein.com/article/905748222-aligos-therapeutics-announces-first-interim-analysis-results-from-the-phase-2-b-supreme-study-of-pevifoscorvir-sodium-in-participants-with-chronic Health Monitor Liechtenstein en PressRelease 2026-04-14T20:05:00+00:00 Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation https://ml.globenewswire.com/media/03ffbe89-c47f-4f83-b51f-f13a572e2cd1/small/aligos-png.png https://healthmonitorliechtenstein.com/article/905748406-structure-therapeutics-appoints-matthew-lang-j-d-as-chief-operating-officer-and-general-counsel Health Monitor Liechtenstein en PressRelease 2026-04-14T20:05:00+00:00 Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel https://ml.globenewswire.com/media/154be1d7-62d7-4688-be20-3b2a10a2628e/small/structure-therapeutics-png.png https://healthmonitorliechtenstein.com/article/905748488-geron-corporation-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4 Health Monitor Liechtenstein en PressRelease 2026-04-14T20:05:00+00:00 Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/e184bb51-5636-436e-8964-15613f24ca1f/small/geron-logo-jpg.jpg https://healthmonitorliechtenstein.com/article/905748979-canadian-animal-health-institute-unleashes-cutest-pets-on-parliament-hill Health Monitor Liechtenstein en PressRelease 2026-04-14T20:00:00+00:00 Canadian Animal Health Institute Unleashes Cutest Pets on Parliament Hill  https://ml.globenewswire.com/media/197c2953-84e0-435d-8524-c68da19d27e9/small/cahi-logo-jpg.JPG https://healthmonitorliechtenstein.com/article/905748980-l-institut-canadien-de-la-sant-animale-lib-re-les-animaux-de-compagnie-les-plus-mignons-sur-la-colline-du-parlement Health Monitor Liechtenstein en PressRelease 2026-04-14T20:00:00+00:00 L’Institut canadien de la santé animale libère les animaux de compagnie les plus mignons sur la Colline du Parlement  https://ml.globenewswire.com/media/197c2953-84e0-435d-8524-c68da19d27e9/small/cahi-logo-jpg.JPG https://healthmonitorliechtenstein.com/article/905736235-national-roundtable-advances-women-s-health-and-chronic-pain-research-in-canada Health Monitor Liechtenstein en PressRelease 2026-04-14T19:17:30+00:00 National Roundtable Advances Women’s Health and Chronic Pain Research in Canada https://ml.globenewswire.com/media/32c18902-bbfd-4447-afb8-37712906af67/small/centre-of-excellence-logo-png.png https://healthmonitorliechtenstein.com/article/905736758-la-table-ronde-nationale-fait-progresser-les-recherches-sur-la-sant-et-la-douleur-chronique-au-canada Health Monitor Liechtenstein en PressRelease 2026-04-14T19:17:30+00:00 La table ronde nationale fait progresser les recherches sur la santé et la douleur chronique au Canada https://ml.globenewswire.com/media/32c18902-bbfd-4447-afb8-37712906af67/small/centre-of-excellence-logo-png.png https://healthmonitorliechtenstein.com/article/905736407-dr-eric-haeger-establishes-new-scholarship-program-to-support-future-medical-professionals-and-healthcare-innovation Health Monitor Liechtenstein en PressRelease 2026-04-14T19:07:19+00:00 Dr. Eric Haeger Establishes New Scholarship Program to Support Future Medical Professionals and Healthcare Innovation https://ml.globenewswire.com/media/46ed0337-1c54-4d9f-b03a-6578ae568fc8/medium/dr-eric-haeger-scholarship.png https://healthmonitorliechtenstein.com/article/905735070-adcare-hospital-hosts-eagle-scout-led-initiative-to-support-patients-in-recovery Health Monitor Liechtenstein en PressRelease 2026-04-14T18:45:00+00:00 AdCare Hospital Hosts Eagle Scout-Led Initiative to Support Patients in Recovery https://ml.globenewswire.com/media/d233fb10-552e-4814-b746-a0797cce4b93/small/logo-adcare-png.png https://healthmonitorliechtenstein.com/article/905735131-exit-156-capital-and-nightware-announce-strategic-investment-partnership Health Monitor Liechtenstein en PressRelease 2026-04-14T18:33:00+00:00 EXIT 156 CAPITAL AND NIGHTWARE ANNOUNCE STRATEGIC INVESTMENT PARTNERSHIP https://ml.globenewswire.com/media/a6f5b4f9-8819-48df-bbb5-58f7d222ab16/small/nightware-inc-logo.png https://healthmonitorliechtenstein.com/article/905734763-microbot-medical-to-highlight-commercial-achievements-leading-to-the-full-market-release-fmr-of-the-liberty-endovascular-robotic-system-at-the Health Monitor Liechtenstein en PressRelease 2026-04-14T18:30:00+00:00 Microbot Medical® to Highlight Commercial Achievements Leading to the Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System at the 25th Annual Needham Virtual Healthcare Conference https://ml.globenewswire.com/media/346df7fb-c134-40c2-970a-39bcbaf974cd/small/mbot-logo-rgb-jpg.jpg https://healthmonitorliechtenstein.com/article/905735393-supporting-women-s-health-can-unlock-workforce-potential-here-s-what-employers-and-allies-can-do Health Monitor Liechtenstein en PressRelease 2026-04-14T18:24:12+00:00 Supporting Women’s Health Can Unlock Workforce Potential. Here’s What Employers and Allies Can Do https://ml.globenewswire.com/media/669af2b2-a5eb-433a-b6da-54ef95a7977b/small/whcc-logo-jpg.jpg https://healthmonitorliechtenstein.com/article/905735430-le-soutien-la-sant-des-femmes-maximise-le-potentiel-de-la-main-d-uvre-voici-comment-les-employeurs-et-les-alli-s-peuvent-aider Health Monitor Liechtenstein en PressRelease 2026-04-14T18:24:12+00:00 Le soutien à la santé des femmes maximise le potentiel de la main-d’œuvre. Voici comment les employeurs et les alliés peuvent aider https://ml.globenewswire.com/media/669af2b2-a5eb-433a-b6da-54ef95a7977b/small/whcc-logo-jpg.jpg https://healthmonitorliechtenstein.com/article/905735110-scripps-encinitas-named-among-top-100-hospitals-in-the-u-s Health Monitor Liechtenstein en PressRelease 2026-04-14T18:17:15+00:00 Scripps Encinitas Named Among Top 100 Hospitals in the U.S. https://ml.globenewswire.com/media/Y2Q0NWE4NGUtZjcyNi00NDM4LWJjMDQtNGRiYWE5MGJkODI4LTExMDA0OTEtMjAyNi0wNC0xNC1lbg==/tiny/Scripps-Health.png https://healthmonitorliechtenstein.com/article/905735261-galera-therapeutics-and-obsidian-therapeutics-announce-merger-agreement-and-350-million-concurrent-private-placement Health Monitor Liechtenstein en PressRelease 2026-04-14T18:08:10+00:00 Galera Therapeutics and Obsidian Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement https://ml.globenewswire.com/media/d4232a7c-0097-427f-af68-18288ab26fa6/small/galera-logo-jpg.jpg https://healthmonitorliechtenstein.com/article/905721688-excellent-brain-ltd-launches-new-android-version-for-neurofeedback-for-adhd-platform Health Monitor Liechtenstein en PressRelease 2026-04-14T17:29:00+00:00 Excellent Brain Ltd. Launches New Android Version for Neurofeedback for ADHD Platform https://pressranger.s3.us-west-1.amazonaws.com/3230185/WhatsApp-Image-2026-04-05-at-12.59.39.jpeg https://healthmonitorliechtenstein.com/article/905721597-van-nuys-premier-rehabilitation-center-injury-docs-celebrates-10-000th-patient Health Monitor Liechtenstein en PressRelease 2026-04-14T16:37:00+00:00 Van Nuys' Premier Rehabilitation Center, Injury Docs, Celebrates 10,000th Patient https://pressranger.s3.us-west-1.amazonaws.com/3228271/SCR-20260410-mizp.png https://healthmonitorliechtenstein.com/article/905707675-ose-immunotherapeutics-evolves-its-leadership-team Health Monitor Liechtenstein en PressRelease 2026-04-14T16:00:00+00:00 OSE Immunotherapeutics Evolves its Leadership Team https://ml-eu.globenewswire.com/media/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22/small/ose-logo-horizontal-rvb-png.png https://healthmonitorliechtenstein.com/article/905707763-ose-immunotherapeutics-fait-voluer-son-quipe-de-direction Health Monitor Liechtenstein en PressRelease 2026-04-14T16:00:00+00:00 OSE Immunotherapeutics fait évoluer son équipe de direction https://ml-eu.globenewswire.com/media/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22/small/ https://healthmonitorliechtenstein.com/article/905708063-comprehensive-healthcare-launches-just-in-time-prescriber-scheduling-to-improve-access-to-behavioral-health-medication-services Health Monitor Liechtenstein en PressRelease 2026-04-14T16:00:00+00:00 Comprehensive Healthcare Launches “Just In Time” Prescriber Scheduling to Improve Access to Behavioral Health Medication Services https://ml.globenewswire.com/media/87b3c91d-8292-48c4-aaff-e3ee4e518ee3/small/ch-logo-jpg.jpg https://healthmonitorliechtenstein.com/article/905708364-providence-saint-john-s-health-center-announces-largest-philanthropic-gift-in-its-history-through-transformative-stan-lucas-legacy Health Monitor Liechtenstein en PressRelease 2026-04-14T16:00:00+00:00 Providence Saint John’s Health Center Announces Largest Philanthropic Gift in Its History Through Transformative Stan Lucas Legacy https://ml.globenewswire.com/media/5cec38c7-016b-458b-b0cf-462a36e4f605/small/saintjohnshealthcenter-2l-clr-4cp-lowerres-jpg.jpg https://healthmonitorliechtenstein.com/article/905708957-ascellahealth-inaugurates-strategic-advisory-council-with-founding-members-advances-pharmacy-benefits-ecosystem-through-technology-deployment-and Health Monitor Liechtenstein en PressRelease 2026-04-14T15:30:00+00:00 AscellaHealth Inaugurates Strategic Advisory Council, With Founding Members, Advances Pharmacy Benefits Ecosystem Through Technology Deployment and Specialty Expertise https://ml.globenewswire.com/media/5278c55f-330c-41a1-8446-d8b1a07bbc55/small/ah-logo-colornotag-4x-png.png https://healthmonitorliechtenstein.com/article/905699380-vietnam-shocks-the-world-with-animal-to-human-organ-transplantation-technology Health Monitor Liechtenstein en PressRelease 2026-04-14T14:56:25+00:00 Vietnam Shocks the World With Animal-To-Human Organ Transplantation Technology https://ml.globenewswire.com/media/8986a8b7-9a74-40ca-bd2f-eef76084e773/medium/vgct-s-source.jpg https://healthmonitorliechtenstein.com/article/905695842-major-shareholder-announcement Health Monitor Liechtenstein en PressRelease 2026-04-14T14:44:22+00:00 Major Shareholder Announcement https://ml-eu.globenewswire.com/media/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce/small/logo-jpg.jpg https://healthmonitorliechtenstein.com/article/905697702-advanced-radiation-centers-of-new-york-launches-softray-therapy-offering-new-non-surgical-relief-of-inflammatory-tendon-and-arthritis-pain Health Monitor Liechtenstein en PressRelease 2026-04-14T14:04:00+00:00 Advanced Radiation Centers of New York Launches SoftRay™ Therapy, Offering New Non-Surgical Relief of Inflammatory, Tendon and Arthritis Pain https://ml.globenewswire.com/media/de310bc0-7bc1-48f5-b455-ca8f8ffd0472/medium/softray-therapy-logo.png https://healthmonitorliechtenstein.com/article/905695461-zealand-pharma-appoints-eric-rojas-as-vice-president-and-head-of-investor-relations Health Monitor Liechtenstein en PressRelease 2026-04-14T14:00:00+00:00 Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations https://ml-eu.globenewswire.com/media/b505bacc-6953-4eb4-ab25-e03008f97b92/medium/eric-rojas.jpg https://healthmonitorliechtenstein.com/article/905696037-award-winning-medical-alert-system-bay-alarm-medical-launches-caregiver-sos-youtube-series-to-support-family-caregivers Health Monitor Liechtenstein en PressRelease 2026-04-14T14:00:00+00:00 Award-winning Medical Alert System Bay Alarm Medical Launches 'Caregiver SOS' YouTube Series to Support Family Caregivers https://pressranger.s3.us-west-1.amazonaws.com/3140430/Screenshot-2026-03-06-at-12.32.15%E2%80%AFPM.png https://healthmonitorliechtenstein.com/article/905696490-neion-bio-strengthens-genome-engineering-leadership-with-appointment-of-colossal-biosciences-veteran-james-kehler Health Monitor Liechtenstein en PressRelease 2026-04-14T14:00:00+00:00 Neion Bio Strengthens Genome Engineering Leadership with Appointment of Colossal Biosciences Veteran James Kehler https://ml.globenewswire.com/media/e37518bc-d9ef-45ce-99a7-35e82f143444/medium/dr-james-kehler.jpg https://healthmonitorliechtenstein.com/article/905696688-reducing-administrative-burden-raises-medicaid-provider-satisfaction-by-50-new-study-finds Health Monitor Liechtenstein en PressRelease 2026-04-14T14:00:00+00:00 Reducing Administrative Burden Raises Medicaid Provider Satisfaction by 50%, New Study Finds https://ml.globenewswire.com/media/24cdff2f-7c95-4f21-aebb-25c4628d94e7/small/gainwell-logo-suite-061720-logosuite-png-gainwell-logo-150-r.png https://healthmonitorliechtenstein.com/article/905697695-hibercell-to-present-preclinical-data-demonstrating-the-enhanced-antitumor-activity-of-hc-7366-in-combination-with-vegfr-tkis-in-clear-cell-renal-cell Health Monitor Liechtenstein en PressRelease 2026-04-14T14:00:00+00:00 HiberCell to Present Preclinical Data Demonstrating the Enhanced Antitumor Activity of HC-7366 in Combination with VEGFR-TKIs in Clear Cell Renal Cell Carcinoma (ccRCC) https://ml.globenewswire.com/media/d168805a-8691-40f2-abcf-fb63a607f112/small/hybercell-jpg.jpg https://healthmonitorliechtenstein.com/article/905697837-grand-river-aseptic-manufacturing-announces-100-million-investment-in-sterile-manufacturing-capabilities Health Monitor Liechtenstein en PressRelease 2026-04-14T13:55:44+00:00 Grand River Aseptic Manufacturing Announces $100 Million Investment in Sterile Manufacturing Capabilities https://ml.globenewswire.com/media/OTBkMmRlZDktNGMxYi00Mjk1LWE0YWMtZTBhYjhlOTMyMTFhLTUwMDE1MTE4Ny0yMDI2LTA0LTE0LWVu/tiny/Grand-River-Aseptic-Manufactur.png https://healthmonitorliechtenstein.com/article/905697955-penn-highlands-healthcare-addresses-community-needs Health Monitor Liechtenstein en PressRelease 2026-04-14T13:44:34+00:00 Penn Highlands Healthcare Addresses Community Needs https://ml.globenewswire.com/media/ZGEyZjE1ZWMtZDA4MC00MmM1LWI0ZmQtNmVlMTM5ODUxMDgzLTEyNTYxMzgtMjAyNi0wNC0xNC1lbg==/tiny/Penn-Highlands-Healthcare.png https://healthmonitorliechtenstein.com/article/905686836-culture-biosciences-announces-strategic-addition-to-its-board-of-directors-to-accelerate-hardware-commercialization-and-saas-growth Health Monitor Liechtenstein en PressRelease 2026-04-14T13:30:00+00:00 Culture Biosciences Announces Strategic Addition to Its Board of Directors to Accelerate Hardware Commercialization and SaaS Growth https://ml.globenewswire.com/media/ce8c1148-eecd-40b0-b1b7-f858ab8c3c4f/small/culture-logo-one-color-rgb-1500px-300ppi-1-1-png.png https://healthmonitorliechtenstein.com/article/905685691-virtuix-delivers-omni-one-to-florida-gulf-coast-university-for-use-in-physical-therapy-and-clinical-simulation Health Monitor Liechtenstein en PressRelease 2026-04-14T13:15:00+00:00 Virtuix Delivers Omni One to Florida Gulf Coast University for Use in Physical Therapy and Clinical Simulation https://ml.globenewswire.com/media/2ba7d28b-48bc-45db-b49e-929295456dc1/medium/omni-one-at-fgu-s-marieb-college-of-health-and-human-service.jpeg https://healthmonitorliechtenstein.com/article/905685932-myriad-genetics-expands-access-for-mychoice-test-to-prostate-cancer-patients-in-japan Health Monitor Liechtenstein en PressRelease 2026-04-14T13:15:00+00:00 Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan https://ml.globenewswire.com/media/5cb679cf-5a10-4b95-8cf7-fd1d0b56721a/small/myriad-s-stacked-png.png https://healthmonitorliechtenstein.com/article/905685481-nextech-reduces-healthcare-s-payment-reconciliation-burden-with-reimagined-embedded-payment-processing-platform Health Monitor Liechtenstein en PressRelease 2026-04-14T13:00:00+00:00 Nextech Reduces Healthcare’s Payment Reconciliation Burden with Reimagined Embedded Payment Processing Platform https://ml.globenewswire.com/media/2b32c79b-9e9d-48d1-ae49-77d47537ae62/small/nextech-logo-jpg-jpg.jpg https://healthmonitorliechtenstein.com/article/905685781-alliance-direct-benefits-launches-alliance-complete-as-demand-grows-for-simplified-bundled-support-offerings Health Monitor Liechtenstein en PressRelease 2026-04-14T13:00:00+00:00 Alliance Direct Benefits Launches Alliance Complete as Demand Grows for Simplified, Bundled Support Offerings https://ml.globenewswire.com/media/ZGM1MDA4YTEtODYzZi00YzgzLThkODAtMjEwNWJhZjU2NjQ2LTUwMDE2MDEwNC0yMDI2LTA0LTE0LWVu/tiny/Alliance-Direct-Benefits.png https://healthmonitorliechtenstein.com/article/905686904-healthedge-partners-with-ellipsis-health-to-scale-care-management-through-ai-powered-virtual-nursing Health Monitor Liechtenstein en PressRelease 2026-04-14T13:00:00+00:00 HealthEdge® Partners with Ellipsis Health to Scale Care Management Through AI-Powered Virtual Nursing https://ml.globenewswire.com/media/18d2dfaf-8f95-4f15-99e6-ae8282b42123/small/healthedge-logo-jpg.jpg https://healthmonitorliechtenstein.com/article/905686993-neomorph-to-highlight-progress-in-targeted-protein-degradation-science-at-the-american-association-for-cancer-research-annual-meeting Health Monitor Liechtenstein en PressRelease 2026-04-14T13:00:00+00:00 Neomorph to Highlight Progress in Targeted Protein Degradation Science at the American Association for Cancer Research Annual Meeting https://ml.globenewswire.com/media/d00180c1-5def-41b6-95c7-018ca5e07565/small/neomorph-logo-jpg.jpg https://healthmonitorliechtenstein.com/article/905687330-haystack-health-appoints-digital-health-leader-bill-snyder-as-chief-executive-officer Health Monitor Liechtenstein en PressRelease 2026-04-14T13:00:00+00:00 Haystack Health Appoints Digital Health Leader Bill Snyder as Chief Executive Officer https://ml.globenewswire.com/media/f6629b37-d06b-4203-a6cd-f233134c4f32/small/hh-logo-png.png https://healthmonitorliechtenstein.com/article/905687785-merakris-therapeutics-and-ifyber-collaboration-receives-top-sawc-research-award-for-mtx-001-wound-healing-study-in-human-skin-model Health Monitor Liechtenstein en PressRelease 2026-04-14T13:00:00+00:00 Merakris Therapeutics and iFyber Collaboration Receives Top SAWC Research Award for MTX-001 Wound Healing Study in Human Skin Model https://ml.globenewswire.com/media/5b9c5fed-3332-4d4d-b8b6-6ab1b15faaed/small/mrks-brand-logo-final-fullcolor-png.png https://healthmonitorliechtenstein.com/article/905685907-just-salad-opens-in-east-amherst-n-y Health Monitor Liechtenstein en PressRelease 2026-04-14T12:57:00+00:00 Just Salad Opens in East Amherst, N.Y. https://ml.globenewswire.com/media/0bfa206d-0a40-4b13-a05a-267ebef25a6a/medium/just-salad-east-amherst-new-york-storefront.jpg https://healthmonitorliechtenstein.com/article/905688308-entera-bio-to-host-key-opinion-leader-webinar-highlighting-the-osteoporosis-treatment-landscape-and-the-opportunity-for-eb613 Health Monitor Liechtenstein en PressRelease 2026-04-14T12:45:00+00:00 Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613 https://ml.globenewswire.com/media/9b4ae2bf-733d-4180-b48c-d0fa3f26c81a/small/logo-png.png https://healthmonitorliechtenstein.com/article/905688406-actuate-therapeutics-announces-nature-medicine-publication-of-clinical-trial-results-showing-doubling-of-the-rate-of-survival-with-elraglusib-plus Health Monitor Liechtenstein en PressRelease 2026-04-14T12:45:00+00:00 Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma https://ml.globenewswire.com/media/f65ca94c-eff8-4376-ac67-ded1b03b3bcc/small/actuatetx-logo-color300-jpg.jpg https://healthmonitorliechtenstein.com/article/905688494-extendicare-announces-closing-of-450-million-inaugural-offering-of-investment-grade-senior-unsecured-notes Health Monitor Liechtenstein en PressRelease 2026-04-14T12:39:06+00:00 Extendicare Announces Closing of $450 Million Inaugural Offering of Investment Grade Senior Unsecured Notes https://ml.globenewswire.com/media/6d631964-eede-4e2c-912c-58ab7d1dc35f/small/extendicare-jpg.jpg https://healthmonitorliechtenstein.com/article/905686858-cellectar-enrolls-first-patient-in-clr-125-auger-emitting-radioconjugate-phase-1b-clinical-trial-targeting-refractory-triple-negative-breast-cancer Health Monitor Liechtenstein en PressRelease 2026-04-14T12:35:00+00:00 Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC) https://ml.globenewswire.com/media/980abc5d-826f-4ac3-ad81-f07d69b34af6/small/cellectar-logo-1-jpg.jpg https://healthmonitorliechtenstein.com/article/905686003-pelthos-therapeutics-to-participate-in-piper-sandler-spring-biopharma-symposium Health Monitor Liechtenstein en PressRelease 2026-04-14T12:30:00+00:00 Pelthos Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium https://ml.globenewswire.com/media/7d71f2d0-a48f-4fe0-a49c-138de21bc0e1/small/pelthos-logo-rgb-png.png https://healthmonitorliechtenstein.com/article/905686896-cytodyn-to-present-at-the-aacr-annual-meeting-2026 Health Monitor Liechtenstein en PressRelease 2026-04-14T12:30:00+00:00 CytoDyn to Present at the AACR Annual Meeting 2026 https://ml.globenewswire.com/media/3b426b4d-6299-4c23-9f95-058174a5b7be/small/new-logo-png.png https://healthmonitorliechtenstein.com/article/905687404-clinical-data-supporting-targeted-chemotherapeutic-delivery-via-renovorx-s-tamp-therapy-platform-presented-at-2026-sir-annual-scientific-meeting Health Monitor Liechtenstein en PressRelease 2026-04-14T12:30:00+00:00 Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting https://ml.globenewswire.com/media/e18bf823-ff44-4bbd-82b9-3a311d58dad8/small/final-logo-horizontal-png.png https://healthmonitorliechtenstein.com/article/905688178-join-nexalin-s-exclusive-live-investor-webinar-and-q-a-session-on-april-21 Health Monitor Liechtenstein en PressRelease 2026-04-14T12:30:00+00:00 Join Nexalin’s Exclusive Live Investor Webinar and Q&A Session on April 21 https://ml.globenewswire.com/media/7f481b55-16b6-4c8a-8356-30d54079a605/small/nexalin-jpg.jpg https://healthmonitorliechtenstein.com/article/905688250-meiragtx-to-present-3-year-data-from-the-phase-1-aquax-clinical-study-of-aav-haqp1-for-the-treatment-of-grade-2-3-radiation-induced-xerostomia-on Health Monitor Liechtenstein en PressRelease 2026-04-14T12:30:00+00:00 MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026 https://ml.globenewswire.com/media/6b45b8d0-975e-494b-8a46-b88360aa1791/small/mgx-logo-png.png https://healthmonitorliechtenstein.com/article/905688290-tomi-reports-strong-q1-2026-sales-of-high-margin-bit-solution-indicating-positive-growth-trends Health Monitor Liechtenstein en PressRelease 2026-04-14T12:30:00+00:00 TOMI Reports Strong Q1 2026 Sales of High-Margin BIT Solution, Indicating Positive Growth Trends https://ml.globenewswire.com/media/f8c7c513-0121-4507-84b7-3680626d9cf3/small/tomi-jpg.jpg https://healthmonitorliechtenstein.com/article/905687539-biomerica-launches-infoods-ibs-in-canada-through-partnerships-with-phoenix-airmid-biomedical-and-canalt-health-labs Health Monitor Liechtenstein en PressRelease 2026-04-14T12:19:00+00:00 Biomerica Launches inFoods® IBS in Canada Through Partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs https://ml.globenewswire.com/media/3461b9f0-3e95-484f-96e9-71608fc20239/small/biomerica-png.png https://healthmonitorliechtenstein.com/article/905673841-inspira-technologies-appoints-yoav-rozanovich-as-chief-business-officer-to-drive-immediate-revenue-growth-and-quantum-expansion Health Monitor Liechtenstein en PressRelease 2026-04-14T12:01:00+00:00 Inspira Technologies Appoints Yoav Rozanovich as Chief Business Officer to Drive Immediate Revenue Growth and Quantum Expansion https://ml.globenewswire.com/media/6a4eabfe-c9ec-40d1-87fc-6f0d8e6e408c/small/screenshot-2025-04-02-at-19-21-06-png.png https://healthmonitorliechtenstein.com/article/905669423-community-routes-access-to-mental-health-care-provides-continued-funding-for-mental-health-services-at-free-charitable-clinics Health Monitor Liechtenstein en PressRelease 2026-04-14T12:00:00+00:00 Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics https://ml-eu.globenewswire.com/media/c2001734-949b-4cc2-8021-b4b64eda1f13/small/teva-rgb-jpeg-jpg.jpg https://healthmonitorliechtenstein.com/article/905669681-amneal-launches-first-two-respiratory-metered-dose-inhalation-products-in-the-u-s Health Monitor Liechtenstein en PressRelease 2026-04-14T12:00:00+00:00 Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S. https://ml.globenewswire.com/media/a20d6f40-90af-422f-ab14-47208fdbad2f/small/amneal-rgb-k-png.png https://healthmonitorliechtenstein.com/article/905669769-biovie-announces-abstract-accepted-for-presentation-at-the-2026-american-academy-of-neurology-annual-meeting Health Monitor Liechtenstein en PressRelease 2026-04-14T12:00:00+00:00 BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting https://ml.globenewswire.com/media/f437d04b-c089-46eb-bca8-7ef64f68bc9b/small/biovie-logo-jpg.jpg https://healthmonitorliechtenstein.com/article/905669779-grace-therapeutics-announces-abstract-highlighting-strive-on-phase-3-trial-results-accepted-for-presentation-at-aan-2026 Health Monitor Liechtenstein en PressRelease 2026-04-14T12:00:00+00:00 Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026 https://ml.globenewswire.com/media/c71c0a95-caed-4520-87a9-ac7fefef3f07/small/grce-logo-jpg.jpg https://healthmonitorliechtenstein.com/article/905670492-er-kim-signs-exclusive-distribution-agreement-with-leo-pharma-a-s-to-commercialize-loqtorzi-toripalimab-for-nasopharyngeal-and-oesophageal-cancers Health Monitor Liechtenstein en PressRelease 2026-04-14T12:00:00+00:00 Er-Kim Signs Exclusive Distribution Agreement with LEO Pharma A/S to Commercialize LOQTORZI® (toripalimab) for Nasopharyngeal and Oesophageal Cancers https://ml.globenewswire.com/media/37d25207-4dc0-4c58-b0cc-d589d363d644/small/erkim-logo-jpg.jpg https://healthmonitorliechtenstein.com/article/905670506-hinge-bio-announces-first-subject-dosed-in-phase-1-trial-of-hb2198-a-novel-b-cell-depleting-agent-for-treating-autoimmune-disease Health Monitor Liechtenstein en PressRelease 2026-04-14T12:00:00+00:00 Hinge Bio Announces First Subject Dosed in Phase 1 Trial of HB2198, a Novel B cell Depleting Agent, for Treating Autoimmune Disease https://ml.globenewswire.com/media/62e1a1c6-154c-4dec-bfb4-79d43b015626/small/hinge-logo-color-2021-jpg.jpg https://healthmonitorliechtenstein.com/article/905671256-genecentric-to-present-data-on-fragmentomics-based-expressct-liquid-biopsy-technology-at-aacr-2026 Health Monitor Liechtenstein en PressRelease 2026-04-14T12:00:00+00:00 GeneCentric to Present Data on Fragmentomics-Based ExpressCT™ Liquid Biopsy Technology at AACR 2026 https://ml.globenewswire.com/media/90d634f2-8dea-4f53-805f-e1e0eaa71133/small/genecentric-logo-jpg.jpg https://healthmonitorliechtenstein.com/article/905671300-rivus-pharmaceuticals-announces-first-patients-dosed-in-amplify-phase-2-trial-for-hu6-in-mash Health Monitor Liechtenstein en PressRelease 2026-04-14T12:00:00+00:00 Rivus Pharmaceuticals Announces First Patients Dosed in AMPLIFY Phase 2 Trial for HU6 in MASH https://ml.globenewswire.com/media/b85bbdee-9fda-4cf2-a14f-d2d608f0b949/small/rivus-pharmaceuticals-logo-png.png https://healthmonitorliechtenstein.com/article/905671534-carlsmed-inc-to-report-first-quarter-2026-financial-results-on-may-5-2026 Health Monitor Liechtenstein en PressRelease 2026-04-14T12:00:00+00:00 Carlsmed Inc. to Report First Quarter 2026 Financial Results on May 5, 2026 https://ml.globenewswire.com/media/ee16eff2-e0d6-40ca-95c5-4dd84bb4cc5f/small/carlsmed-png.png https://healthmonitorliechtenstein.com/article/905671584-nanox-announces-collaboration-with-meir-medical-center-to-deploy-nanox-arc-for-orthopedic-imaging-clinical-study Health Monitor Liechtenstein en PressRelease 2026-04-14T12:00:00+00:00 Nanox Announces Collaboration with Meir Medical Center to Deploy Nanox.ARC for Orthopedic Imaging Clinical Study https://ml.globenewswire.com/media/57c1ffd6-84b3-46b9-b9b3-76666e6ba5a2/small/nano-logo-002-jpg.jpg https://healthmonitorliechtenstein.com/article/905672627-corbus-pharmaceuticals-announces-last-patient-first-visit-in-canyon-1-study-of-crb-913-for-the-treatment-for-obesity Health Monitor Liechtenstein en PressRelease 2026-04-14T12:00:00+00:00 Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity https://ml.globenewswire.com/media/459d6fb1-b336-4d47-8aa1-f9198bda891d/small/corbus-logo-jpg.jpg https://healthmonitorliechtenstein.com/article/905672678-tempest-appoints-andrew-fang-ph-d-as-head-of-business-development-to-advance-strategic-partnerships-and-global-licensing-efforts Health Monitor Liechtenstein en PressRelease 2026-04-14T12:00:00+00:00 Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts https://ml.globenewswire.com/media/6ddb04fb-e5ac-416b-b90b-b4cbf51dc538/small/blue-logo-stacked-jpg.jpg https://healthmonitorliechtenstein.com/article/905672686-genvor-announces-strategic-memorandum-of-understanding-with-canlab-international-to-advance-commercial-peptide-pipeline Health Monitor Liechtenstein en PressRelease 2026-04-14T12:00:00+00:00 Genvor Announces Strategic Memorandum of Understanding with Canlab International™ to Advance Commercial Peptide Pipeline https://ml.globenewswire.com/media/8533fef9-aa8f-43c5-9088-39ab06147641/small/43464-png.png https://healthmonitorliechtenstein.com/article/905672832-real-world-evidence-and-industry-momentum-builds-for-imdx-s-flagship-graftassure-assay Health Monitor Liechtenstein en PressRelease 2026-04-14T12:00:00+00:00 Real-World Evidence and Industry Momentum Builds for iMDx’s Flagship GraftAssure Assay https://ml.globenewswire.com/media/418fe8d1-a6a4-4025-84ba-56f14ee83865/small/imdx-logo-png.png https://healthmonitorliechtenstein.com/article/905673675-calidi-biotherapeutics-announces-speaker-presentation-at-iovc-conference-in-reykjav-k-iceland-on-april-28th-highlighting-the-redtail-platform-s Health Monitor Liechtenstein en PressRelease 2026-04-14T12:00:00+00:00 Calidi Biotherapeutics Announces Speaker Presentation at IOVC Conference in Reykjavík, Iceland on April 28th Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy https://ml.globenewswire.com/media/9e574b79-be62-4805-a4b4-cb0b7dcc5fbd/small/calidibiotherapeutics-logo-2x-jpg.jpg https://healthmonitorliechtenstein.com/article/905674131-aclarion-receives-pinnacle-award-for-ai-innovation Health Monitor Liechtenstein en PressRelease 2026-04-14T12:00:00+00:00 Aclarion Receives Pinnacle Award for AI Innovation https://ml.globenewswire.com/media/6650177f-80b7-4c94-afb4-fc63aa3ada98/small/logo-png.png https://healthmonitorliechtenstein.com/article/905674226-r1-announces-revenue-performance-solutions-powered-by-phare-os-to-help-providers-navigate-growing-complexity-and-margin-pressure Health Monitor Liechtenstein en PressRelease 2026-04-14T12:00:00+00:00 R1 Announces Revenue Performance Solutions Powered by Phare OS to Help Providers Navigate Growing Complexity and Margin Pressure https://ml.globenewswire.com/media/728189a4-e254-443f-8452-315403fd70f4/small/r1-logo-black-25-947x676-jpg.jpg https://healthmonitorliechtenstein.com/article/905674385-prenetics-im8-health-partners-with-vitamin-angels-to-combat-global-malnutrition-commits-to-impacting-400-000-mothers-and-children-in-year-one Health Monitor Liechtenstein en PressRelease 2026-04-14T12:00:00+00:00 Prenetics’ IM8 Health Partners with Vitamin Angels to Combat Global Malnutrition, Commits to Impacting 400,000 Mothers and Children in Year One https://ml.globenewswire.com/media/106dbe1a-a6e1-49d9-97a2-c5609258bdc7/small/pre-logo-2026-png.png https://healthmonitorliechtenstein.com/article/905674450-clairity-announces-update-to-nccn-guidelines-to-include-ai-mammogram-based-risk-tool-to-identify-future-breast-cancer-risk-in-women-missed-by Health Monitor Liechtenstein en PressRelease 2026-04-14T12:00:00+00:00 Clairity Announces Update to NCCN Guidelines to Include AI Mammogram-Based Risk Tool to Identify Future Breast Cancer Risk in Women Missed by Traditional Methods https://ml.globenewswire.com/media/0087b812-cef6-4183-8b7c-093385f3bcb5/small/clairitylogo-fullcolor-vertical-rgb-png.png https://healthmonitorliechtenstein.com/article/905671949-avita-medical-announces-positive-interim-results-from-cohealyx-study-demonstrating-accelerated-time-to-skin-grafting Health Monitor Liechtenstein en PressRelease 2026-04-14T11:45:00+00:00 AVITA Medical Announces Positive Interim Results from Cohealyx® Study Demonstrating Accelerated Time to Skin Grafting https://ml.globenewswire.com/media/53ad8139-952a-4470-9ede-2f3bf0521f16/small/avita-png.png https://healthmonitorliechtenstein.com/article/905674267-clearmind-medicine-s-cmnd-100-meets-primary-endpoint-in-fda-approved-phase-i-iia-clinical-trial-for-alcohol-use-disorder Health Monitor Liechtenstein en PressRelease 2026-04-14T11:32:00+00:00 Clearmind Medicine’s CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder https://ml.globenewswire.com/media/bd17cbf4-8124-4f86-8a4c-1fafbb6785af/small/logo-jpg.jpg https://healthmonitorliechtenstein.com/article/905670306-sanara-medtech-inc-to-report-first-quarter-2026-financial-results-on-may-12-2026 Health Monitor Liechtenstein en PressRelease 2026-04-14T11:30:00+00:00 Sanara MedTech Inc. to Report First Quarter 2026 Financial Results on May 12, 2026 https://ml.globenewswire.com/media/591eb30b-d3e4-428c-9cd6-536215925b01/small/logo-jpg.jpg https://healthmonitorliechtenstein.com/article/905671016-profound-medical-to-participate-in-the-2026-bloom-burton-co-healthcare-investor-conference Health Monitor Liechtenstein en PressRelease 2026-04-14T11:30:00+00:00 Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference https://ml.globenewswire.com/media/94d9e057-9de3-430c-9a19-b41ff3e06a1e/small/profound-logo-cmyk-copy-jpg.jpg https://healthmonitorliechtenstein.com/article/905671585-praxis-precision-medicines-announces-fda-acceptance-of-new-drug-application-for-ulixacaltamide-hcl-in-patients-with-essential-tremor Health Monitor Liechtenstein en PressRelease 2026-04-14T11:30:00+00:00 Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor https://ml.globenewswire.com/media/bff1e728-30ed-46c6-81e1-8bbc795929c0/small/01-primarylogo-color-bluex-100-jpg.jpg https://healthmonitorliechtenstein.com/article/905672048-anavex-life-sciences-highlights-new-scientific-findings-on-shared-biology-between-autism-and-alzheimer-s-disease Health Monitor Liechtenstein en PressRelease 2026-04-14T11:30:00+00:00 Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease https://ml.globenewswire.com/media/1b0f858f-4f7f-4f50-b691-a25307283fb5/small/anavexlogor-transparent-3x-png.png https://healthmonitorliechtenstein.com/article/905674084-medicenna-to-present-at-the-2026-bloom-burton-co-healthcare-investor-conference Health Monitor Liechtenstein en PressRelease 2026-04-14T11:30:00+00:00 Medicenna to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference https://ml.globenewswire.com/media/1644a38b-bed9-4a76-96fa-d57dd028e650/small/medicenna-jpg.jpg https://healthmonitorliechtenstein.com/article/905674299-avacta-ceo-christina-coughlin-named-as-one-of-in-vivo-s-2026-rising-leaders Health Monitor Liechtenstein en PressRelease 2026-04-14T11:26:11+00:00 Avacta CEO Christina Coughlin Named as One of In Vivo's 2026 Rising Leaders https://ml.globenewswire.com/media/63584766-21c6-42e8-944c-7103432b045b/small/avacta-logo-full-color-rgb-oct-2024-jpg.jpg https://healthmonitorliechtenstein.com/article/905669756-adagene-adds-industry-veteran-peter-lebowitz-to-scientific-and-strategic-advisory-board Health Monitor Liechtenstein en PressRelease 2026-04-14T11:00:00+00:00 Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board https://ml.globenewswire.com/media/c377318b-edf7-42c0-8e7c-63a02bbe47b0/small/adagene-logo-gnw-png.png